PR | SCM

본문 바로가기

PR

For a better future SCM Lifescience will do its best

Notice

15

2022.11

[Key Question 5] Clinical pipeline progress

Dear Shareholders,The clinical progress as of April 26, 2022, which showed many questions and interests, is as follows.1..
15

2022.11

[Main Question 4] Company's official position on the shareholder meeti..

Dear Shareholders,Recently, some shareholders have expressed negative opinions about the company through online media an..
15

2022.11

[Main Question 3] Company answer to CoImmune progress

Dear Shareholders,At the 8th regular general meeting of shareholders, we will inform you of the progress of CoImmune,as ..
15

2022.11

[Main Question 2] Corporate answer to Governance Stabilization

Dear Shareholders,Due to the death of the late CEO Sun-Uk Song, many shareholders gave a lot of opinions on how to stabi..
15

2022.11

[Main Question 1] Company's position on malicious rumors related to th..

Dear shareholders,We would like to inform you about the measures taken by SCM Life Sciences in response to the passing o..

1 2 3